PubMed · 14890375
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1951-12-28. SPHYGMOMANOMETER and its interpretations.. https://pubmed.ncbi.nlm.nih.gov/14890375/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Mechanical skin irritation creates vasodilatation in the line of a stroke and in the surrounding tissue. To obtain further insight on underlying physiological mechanisms we developed a model of the vascular network comprised of three layers, where the first and the last one have a tree structure. They represent the arterial and the venous system, respectively. Both are connected via an intermediate zone representing the core of the microcirculation, which is described by means of a compliant compartment model. Irritation induces change in compliance of vessels situated at the entrance of the intermediate zone. Thus the model describes flow and pressure behavior due to mechanical skin irritation.
In this paper, a class of conditional mixed models is proposed to adjust for non-ignorable drop-out, while also accommodating unequal follow-up due to staggered entry and administrative censoring in longitudinal studies. Conditional linear and quadratic models which model subject-specific slopes as linear or quadratic functions of the time-to-drop-out, as well as pattern mixture models are both special cases of this approach. We illustrate these models and compare them with the usual maximum likelihood approach assuming ignorable drop-out using data from a multi-centre randomized clinical trial of renal disease. Simulations under various scenarios where the drop-out mechanism is ignorable and non-ignorable are employed to evaluate the performance of these models.
High blood pressure (BP) ranks as the greatest risk factor for cardiovascular disease. The increased cardiovascular risk determined in recent interventional studies has led the health authorities in some countries to re-ignite the discussion about whether hypertension should be listed as a contraindication for hormone replacement therapy (HRT). We reviewed papers published since 1960 and listed in MEDLINE, EMBASE and Biosis, on studies that monitored the course of BP during HRT. We found that both primarily normotensive and hypertensive postmenopausal women actually run only a very low risk of BP increase during HRT, indeed, BP was often lowered. In one of our own studies 1397 hypertensive women with BP diastolic >95 mmHg received transdermal HRT regimens; BP was lowered by an average of 7 mmHg systolic and 9 mmHg diastolic. The results of the more recent 24-h ambulatory BP studies are particularly conclusive. At least 19 such studies have been performed, 13 placebo-controlled and 10 cross-over; 5 found no effect on BP and 14 studies demonstrated BP reductions. BP was lowered by treatment with transdermal estradiol in 11 of 13 studies and by oral estrogen in 4 of 11 studies. The effects were not consistent with regard to systolic or diastolic BP nor to action on day- and night-time BP. It cannot be ruled out that some women with a particular predisposition exhibit an abnormal reaction to the vasoactive effects of HRT, and there is a paucity of long-term data on risk populations, specifically on the progestogenic effects in patients with pre-existing arteriosclerotic lesions. In conclusion, the risk of developing hypertension during HRT is very low, but hormone therapy should always be appropriately indicated and during therapy BP should be checked regularly.